BTIG Reiterates Buy Rating on Aldeyra Therapeutics (ALDX)

March 17, 2025 5:18 AM EDT Send to a Friend
BTIG analyst Thomas Shrader reiterated a Buy rating and $11.00 price target on Aldeyra Therapeutics (NASDAQ: ALDX)The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login